Skip to main content

Theodore O'Neill

Analyst

Litchfield Hills Research

Equibles does not estimate personal net worth.

About Theodore O'Neill

Theodore O'Neill is recorded as Analyst at Litchfield Hills Research. Theodore O'Neill has spoken on 19 earnings calls and 2 other investor events across 10 companies, most recently for Marti Technologies, Inc. on August 19, 2026. Those appearances were for Travelzoo (TZOO), Star Equity Holdings, Inc. (STRR), Lesaka Technologies Inc (LSAK), uCloudlink Group Inc. (UCL), Bel Fuse Inc (BELFA) and 5 other companies. The companies whose calls Theodore O'Neill spoke on are classified in the Communication Services, Industrials, Technology and Healthcare sectors.

Theodore O'Neill on recent calls

“Cancute, last quarter you talked about gross profit margin having a ceiling of 78%, And I'm wondering if that's still the ceiling you're looking at. And if you feel that this kind of gross profit margin might attract competitors.”
Analyst — Litchfield Hills Research, Second Quarter 2026 Earnings Conference Call ·
“The first is about memory chips and sort of the supply chain of semiconductors in general. You cited here, which everyone has been seeing is memory chip cost increases.”
Analyst — Litchfield Hills Research, uCloudlink Group Inc. Second Quarter 2026 Earnings Conference Call ·
“I'm struck by how Well Energy Services is doing. And, Rick, I wonder if you could talk about, you know, it's up year over year, but it's also up sequentially. Can you give us some more detail on what's going on there?”
Analyst — Litchfield Hills Research, Star Equity Holdings’ Second Quarter 2026 Financial Results Conference Call ·
“So, Holger, if you could give us some more detail on what's happening with advertisers and travelers. You say in the prepared remarks here that conflicts are creating uncertainty.”
Analyst — Litchfield Hills Research, Travelzoo Q2 2026 Earnings Conference Call ·
“I wanted to ask about the Impetus Bioscience Agreement, and could you give us some more information about what indications the JAK inhibitors are for, and do you expect there to be any milestones for your relationship with them beyond this in 2026?”
Analyst — Litchfield Hills Research, Vyome Holdings, Inc Q1 FY2026 Earnings Call ·

Affiliation history

  • Litchfield Hills Research

    Analyst

    Source not stated

    Current

Company network

Recent activity

Show 9 earlier activities